2017_SBRT_Course Book

Oligometastases: prostate cancer

Systematic review: SABR in oligorecurrences limited to lymph nodes

• 363 patients, 9 studies; 211 treated with SBRT to 270 lymph nodes • Mean BED 3Gy in fractionated SBRT ranged from 88-216 Gy • Median follow-up of 19.2 months; local control in 98% of patients. • Median Pprogression Free Survival (biochemical and/or radiological progression) 22.5 months (range, 11-30) • Median ADT-free survival was 32.8 months (range, 25-44) • Acute and/or late grade ≥2 toxicity in 6%; no grade 4 toxicity CONCLUSIONS: • SBRT is promising but weak level of evidence based on retrospective studies of single-institution or pooled experiences

Ponti E, Eur Urology Focus 2017